Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis
GAITHERSBURG, Md. and NEW YORK , Dec. 29, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE: EBS) and Mount Sinai Health System today announced initiation of the clinical program to evaluate...
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance
Reports strong third quarter and record year to date performance Updates full year guidance — refines revenue ranges and raises profitability ranges GAITHERSBURG, Md. , Nov. 05, 2020 (GLOBE...
Emergent BioSolutions to Release Third Quarter 2020 Financial Results and Conduct Conference Call on November 5, 2020
GAITHERSBURG, Md. , Oct. 15, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 5, 2020 at 5:00 pm (Eastern Time) to discuss the...
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19
NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as...
Emergent BioSolutions Applauds Pharmacy Leaders on Consensus Guidelines for Naloxone
First-ever Canadian national consensus guidelines which recommend all patients receiving an opioid should be dispensed take-home naloxone and counselled by a pharmacist. MISSISSAUGA, ON, Sept. 24,...
Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day
‘- Organizations Join Together to Raise Awareness of Overdose Reversal Medicines During August 31st Games GAITHERSBURG, Md. , Aug. 31, 2020 (GLOBE NEWSWIRE) — Emergent...
Emergent BioSolutions Announces Appointment of Marvin White to the Company’s Board of Directors
GAITHERSBURG, Md. , Aug. 26, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company’s board of directors appointed Marvin L. White as a Class II...
Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months
GAITHERSBURG, Md. , Aug. 17, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the...
Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028
GAITHERSBURG, Md. , Aug. 07, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has completed its previously announced offering of $450...
Emergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028
GAITHERSBURG, Md. , Aug. 04, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has priced its offering of $450 million aggregate...
Emergent BioSolutions Announces Proposed Offering of $400 Million of Senior Unsecured Notes
GAITHERSBURG, Md. , Aug. 04, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it intends to offer $400 million aggregate principal amount...
Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 Guidance
Establishes key collaborations with industry, U.S. government, and health care providers to help advance COVID-19 vaccine and therapeutic solutions Current quarter and year-to-date performance...